Elevance Health Inc.

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

Bernstein reaffirms Buy for Elevance Health stock

Analyst upgrade Earnings report Guidance raised AI-generated analysis

πŸ“ˆ Bernstein reaffirmed a Buy rating for Elevance Health on October 5, 2026, keeping the price target at USD 488.00.

πŸ’° Q2 2026 revenue increased by 1.39% to USD 50.47 billion, demonstrating continued top-line growth in the healthcare sector.

πŸ“‰ Net profit fell sharply by 16.09% to USD 1.46 billion in Q2 2026, signaling rising operational or medical cost pressures.

🎯 Management raised full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00 despite recent quarterly headwinds.

πŸ“… The company will report third-quarter 2026 results on October 21, 2026, with management commentary scheduled for 8:30 a.m. EDT.

πŸ“Š Elevance Health trades at a market capitalization of USD 85.6 billion, maintaining its status as a large-cap healthcare leader.

πŸ“‰ The stock is currently trading below its 52-week high of USD 436.24 but remains above the primary market quote of USD 394.51.

Bullish Signals
  • Bernstein maintained a Buy rating and a USD 488.00 price target for Elevance Health, indicating analyst confidence in the stock's long-term prospects.
  • The company raised its full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00, demonstrating management's ability to set ambitious yet achievable financial goals.
  • Revenue grew by 1.39% year-over-year in Q2 2026 to reach USD 50.47 billion, showing resilience and continued market expansion despite macroeconomic headwinds.
Risk Factors
  • Net profit declined by 16.09% to USD 1.46 billion in Q2 2026, raising concerns about margin compression and rising medical spending costs.
  • The significant drop in net income despite revenue growth suggests that operating expenses or claims costs are outpacing top-line gains, a key risk for future profitability.
Full Analysis
Elevance Health received a reaffirmed Buy rating from Bernstein on October 5, 2026, with the analyst maintaining a price target of USD 488.00. At the time of the report, Elevance Health stock was trading around EUR 352.45 (USD 394.51), sitting below its 52-week high of USD 436.24 but above the primary market quote. The large-cap insurer has a market capitalization of approximately USD 85.6 billion, reflecting its significant position in the healthcare plans sector. Financial performance for the second quarter of 2026 showed mixed results, with revenue growing by 1.39% to USD 50.47 billion compared to the prior year. However, net profit declined significantly by 16.09%, dropping from USD 1.74 billion to USD 1.46 billion. This divergence between top-line growth and bottom-line contraction highlights increasing pressure on operating costs and medical spending, which will be central to future earnings discussions. Looking ahead, Elevance Health raised its full-year 2026 adjusted earnings-per-share guidance to at least USD 27.00. The company is scheduled to release its third-quarter 2026 results on October 21, 2026, providing investors a key checkpoint to evaluate the sustainability of revenue growth against rising medical cost trends and the recent profit decline reported in Q2. Analysts will be closely monitoring how management addresses the margin compression evident in the second quarter during the upcoming earnings call. The gap between the current trading price and Bernstein's target suggests potential upside if the company can successfully navigate the challenging cost environment while maintaining its revenue trajectory.